Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74


Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Apr 11:JCO2017771485. doi: 10.1200/JCO.2017.77.1485. [Epub ahead of print]


Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.

Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P.

Target Oncol. 2018 Apr 6. doi: 10.1007/s11523-018-0561-6. [Epub ahead of print]


Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Mar 29. pii: S1078-1439(18)30075-9. doi: 10.1016/j.urolonc.2018.02.018. [Epub ahead of print] Review.


Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more.

Zahoor H, Rini BI, Ornstein MC.

Oncotarget. 2017 Dec 6;9(18):14036-14037. doi: 10.18632/oncotarget.23005. eCollection 2018 Mar 6. No abstract available.


Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P.

Clin Genitourin Cancer. 2018 Feb 22. pii: S1558-7673(18)30118-6. doi: 10.1016/j.clgc.2018.02.002. [Epub ahead of print]


Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma.

Emamekhoo H, Dhillon P, Gopalakrishnan D, Elson P, Stephenson A, Magi-Galluzzi C, McKenney J, Harper H, Haber GP, Kaouk J, Lee B, Fergany A, Berglund R, Gong M, Stein R, Krishnamurthi V, Gilligan T, Ornstein M, Rini B, Garcia J, Grivas P.

Clin Genitourin Cancer. 2018 Feb 6. pii: S1558-7673(18)30073-9. doi: 10.1016/j.clgc.2018.01.014. [Epub ahead of print]


Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9.


Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.

Lucke-Wold B, Seidel K, Udo R, Omalu B, Ornstein M, Nolan R, Rosen C, Ross J.

J Neurol Neurosurg. 2017;4(2). pii: 140. Epub 2017 Dec 7.


Fear, family and the placing of emotion: Black women's responses to a breast cancer awareness intervention.

Brown T, Dyck I, Greenhough B, Raven-Ellison M, Dembinsky M, Ornstein M, Duffy SW.

Soc Sci Med. 2017 Dec;195:90-96. doi: 10.1016/j.socscimed.2017.10.037. Epub 2017 Nov 20.


Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.

Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P.

Clin Genitourin Cancer. 2018 Apr;16(2):e437-e442. doi: 10.1016/j.clgc.2017.10.005. Epub 2017 Oct 17.


Emerging immunotherapy in advanced renal cell carcinoma.

Mendiratta P, Rini BI, Ornstein MC.

Urol Oncol. 2017 Dec;35(12):687-693. doi: 10.1016/j.urolonc.2017.08.011. Epub 2017 Sep 8. Review.


The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.

Barata PC, Ornstein MC, Garcia JA.

J Kidney Cancer VHL. 2017 May 11;4(2):10-18. doi: 10.15586/jkcvhl.2017.69. eCollection 2017. Review.


A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI.

J Clin Oncol. 2017 Jun 1;35(16):1764-1769. doi: 10.1200/JCO.2016.71.1184. Epub 2017 Jan 23.


Suppression menstruelle en présence de circonstances particulières.

Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S.

J Obstet Gynaecol Can. 2016 Dec;38(12S):S484-S495. doi: 10.1016/j.jogc.2016.09.058. Epub 2017 Jan 4. No abstract available.


Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.

Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists.

Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294.


Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?

Ornstein MC, Rini BI.

Clin Cancer Res. 2016 Dec 1;22(23):5626-5628. Epub 2016 Sep 23.


Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition.

Ornstein MC, Garcia JA, Sharifi N.

Transl Androl Urol. 2016 Aug;5(4):616-9. doi: 10.21037/tau.2016.05.13. No abstract available.


Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood L, Elson P, Allman K, Beach J, Martin A, Gilligan T, Garcia JA, Rini BI.

Clin Genitourin Cancer. 2017 Apr;15(2):e275-e280. doi: 10.1016/j.clgc.2016.08.014. Epub 2016 Aug 18.


Review of gynecologic and reproductive care for women with developmental disabilities.

Abells D, Kirkham YA, Ornstein MP.

Curr Opin Obstet Gynecol. 2016 Oct;28(5):350-8. doi: 10.1097/GCO.0000000000000299. Review.


The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.

Ornstein MC, Rini BI.

Expert Rev Anticancer Ther. 2016 Jun;16(6):577-84. doi: 10.1080/14737140.2016.1184980. Epub 2016 May 17. Review.


Supplemental Content

Loading ...
Support Center